FDA Delays Mitapivat Sickle Cell Decision to 2027, Stock Drops but Bull Thesis Holds

What happened

The FDA extended the PDUFA date for mitapivat's sNDA in sickle cell disease to February 2027, triggering a more than 15% drop in Agios stock. The delay centers on safety and REMS considerations, not efficacy, and updated safety data showed no new hepatocellular injury cases. Mitapivat's efficacy in SCD remains mixed, having missed the pain crisis endpoint but demonstrating strong reductions in transfusion burden. Despite the setback, the core bull thesis remains intact because Agios's value is anchored by its launched thalassemia and PK deficiency products, with SCD as a longer-dated call option. The selloff appears to be an overreaction, as the SCD opportunity was already heavily discounted after the ambiguous Phase 3 results.

Implication

The delay extends the timeline for any SCD contribution, and investors should not expect meaningful revenue from SCD before 2028 at the earliest. The core investment case still hinges on AQVESME's launch execution under REMS, which remains the primary driver of value creation. The selloff may offer an attractive entry point if shares approach the $25 level, as the enterprise value ex-cash becomes even more compressed. However, continued uncertainty around SCD and the need for FDA engagement in 2027 will keep a cap on valuation until there is clarity. Investors should monitor early AQVESME launch metrics (certified prescribers and pharmacies) as the key near-term catalyst, as SCD is now a longer-dated binary.

Thesis delta

The thesis shifts from expecting near-term SCD regulatory clarity (pre-sNDA in Q1 2026) to a delayed decision in February 2027, which reduces the option value of SCD but does not break the core bull case. The delay extends the time horizon for the second indication and increases the importance of AQVESME execution. Consequently, the investment case becomes more dependent on commercial uptake of AQVESME, and the bear case scenario probability modestly increases if SCD is ultimately blocked after the extended review.